secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004120
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports preliminary Q4 rev ~$52M; sparsentan PDUFA Feb 17, 2023
-----------------------------------------------------------------------

- Preliminary net product sales Q4 2022 ~$52M; full year 2022 net product sales ~$201M, total revenue $212M.
- Ended 2022 with ~$450M in cash, cash equivalents, and marketable securities.
- FDA PDUFA for sparsentan in IgAN set for Feb 17, 2023; potential Q1 2023 launch if approved.
- Phase 3 PROTECT (IgAN) topline confirmatory results expected Q4 2023; DUPLEX (FSGS) topline Q2 2023.
- Phase 3 trial for pegtibatinase (HCU) to begin H2 2023; RESTORE study for CTX completion expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/d436263d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer